Key Highlights
- This company's shares are trading at $4.80 in pre-market activity, down 3.90% from Wednesday's close of $5.00.
- The company received FDA 510(k) clearance for TriNav Advance, expanding its Pressure-Enabled Drug Delivery portfolio for liver embolization procedures.
- TriNav Advance adds access to small, distal vessels via a compatible delivery microcatheter while preserving the platform's off-target protection.
- The company plans to begin a limited market release of the device over the coming weeks.
Shares Fall Even After a Positive Regulatory Milestone
This NASDAQ-listed oncology medical technology company is trading lower pre-market despite announcing FDA 510(k) clearance for TriNav Advance, the newest device in its Pressure-Enabled Drug Delivery portfolio for liver embolization procedures. The decline suggests the market is treating the clearance as an incremental product line extension rather than a major near-term Revenue catalyst, even though the news itself is a positive regulatory development for the company.
New Device Expands Access to Smaller Vessels
TriNav Advance, marketed by TriSalus Life Sciences (NASDAQ:TLSI), expands the company's device portfolio by adding access to small, distal vessels through a compatible delivery microcatheter, while preserving the platform's enhanced therapeutic delivery and off-target protection. The device can be used in two configurations, a telescoping setup for smaller, distal vessels and a high-flow setup for standard infusion through a large lumen, giving interventional radiologists added flexibility across a broader range of procedures and anatomies. The company plans to begin a limited market release of the device over the coming weeks.
A Focused Oncology Device and Immunotherapy Pipeline
TriSalus Life Sciences is a Westminster, Colorado-based oncology-focused medical technology and biopharmaceutical company dedicated to transforming outcomes for patients with difficult-to-treat liver and pancreatic cancers. The company markets three FDA-cleared devices built on its proprietary Pressure-Enabled Drug Delivery technology, alongside its investigational immunotherapeutic candidate nelitolimod, a Toll-like receptor 9 agonist that has completed three Phase 1 Clinical Trials and for which the company is now exploring Partnership opportunities.






Please wait processing your request...